Damian deGoa served as the CEO of Liquidia Corporation, a biopharmaceutical company, from January 2020 until January 2022. He has a solid foundation in business, having earned a Bachelor's degree in Business Administration. During his time as CEO, deGoa's biggest...
Damian deGoa served as the CEO of Liquidia Corporation, a biopharmaceutical company, from January 2020 until January 2022. He has a solid foundation in business, having earned a Bachelor's degree in Business Administration. During his time as CEO, deGoa's biggest achievement came after Liquidia received tentative FDA approval for its drug LIQ861, which propelled the company's growth. He received a total compensation of $47162 in 2022, which was a significant drop from over $988k in 2021, as he transitioned to a non-employee role on the board after resigning. Damian is notable for having been granted a stock option for 2 million shares at an exercise price of $3.00 per share but no vested stock was reported during his final year. After leaving his role as CEO, he continues to contribute to Liquidia as a board member. His experience and strategic decisions have made a lasting impact on the firm during a crucial growth period.